The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

NARBERTH, Pennsylvania (WPVI) -- "Take A Breather Foundation" based in Narberth is a stress relief outlet for people with cystic fibrosis. Their focus is to provide a "breather" to their recipients, ...

Despite the existence of numerous clinical practice guidelines (CPGs) for cystic fibrosis (CF), there is limited understanding of their credibility and consistency. This systematic review aims to ...

Researchers at Imperial College London are leading human trials for the innovative treatmentAn inhalable medicine with the potential to improve lung ...

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

Tauranga boy Riaan Hamilton has cystic fibrosis – the 3-year-old often gets sick, has been hospitalised several times, and is ...

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...